No Data
We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate
Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $17
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $16
JMP Securities Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $21
Eli Lilly in Talks to Acquire Scorpion Therapeutics, FT Says; Relay Therapeutics Surges
Express News | Relay Therapeutics Shares Resume Trade Following Circuit Breaker Halt